INT Contour

by Carina Medical  · Based in United States → — Revolutionizing Healthcare Through the Power of AI
Nuclear Medicine Oncology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Carina Medical is a developer of artificial intelligence (AI)-based medical image analysis software designed for radiation oncology and radiology applications. The company’s software provides novel technologies for efficient radiation treatment, assisting in both computed tomography (CT) and magnetic resonance imaging (MRI)-based organ segmentation and site-specific segmentation models to enhance the robustness of the AI system. This enables doctors with an efficient workflow for radiation therapy and aims to improve cancer treatment.

INTContour, specifically, offers fully customizable AI-powered Organ-at-Risk (OAR) and Target Segmentation with Automatic Quality Assurance. It can automatically segment over 120 organs and lymph node groups from CT, MRI, and PET/CT modalities using built-in or custom protocols. Beyond automated segmentation, INTContour provides robust quality assurance features for segmentation validation and includes tools for manual segmenting and annotations, allowing for consistent user control and analysis across all studies.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-Powered OAR & Target Segmentation
  • Automatic Quality Assurance (Dice Score, Mean Surface Distance, Hausdorff Distance calculation)
  • Customizable AI protocols for segmentation
  • Segmentation of over 120 organs & lymph node groups
  • Support for CT, MRI, and PET/CT modalities
  • Tools for manual segmenting & annotations
  • Operates as a stand-alone web-based system
  • Integrates via Automatic Workflow or TPS Connectivity
  • Research tools for training models without coding
  • Advanced editing & analysis including gross total volume calculation and Smart Interpolation

Use Cases

  • Radiation therapy treatment planning
  • Automatic segmentation of organs at risk (OAR)
  • Automatic segmentation of target volumes (e.g., tumors, lymph nodes)
  • Quality assurance for medical image segmentation
  • Streamlining research and model training in radiation oncology
  • Improving efficiency and accuracy in cancer treatment planning

What Physicians Need to Know

Key Capabilities
INT Contour offers fully customizable AI-powered segmentation for over 120 organs and lymph node groups across CT, MRI, and PET/CT modalities. It includes robust quality assurance features, automatically generating reports with metrics like Dice Score, Mean Surface Distance, and Hausdorff Distance. The tool provides an interactive study viewer with advanced editing and analysis features, including Smart Interpolation to reduce annotation time. It also supports incremental learning for training custom models and batch processing for large datasets. The system can replace Protected Health Information (PHI) with anonymized values in longitudinal studies while preserving DICOM-RT data links.
Clinical Utility
The tool supports the radiation therapy treatment planning process by automatically segmenting treatment targets and organs at risk (OARs). It has been shown to improve workflow efficiency by significantly reducing contouring time compared to manual methods, even with professional review and edits. AI autocontours are generally considered clinically acceptable, often requiring only minor adjustments from healthcare professionals. Supported anatomical regions for automatic segmentation include the head and neck, thorax, abdomen, and male pelvis.
Integration Options
INT Contour can operate as a standalone web-based system or integrate seamlessly with existing applications via Automatic Workflow or Treatment Planning System (TPS) Connectivity. It efficiently segments studies and transfers DICOM-RT data back to the main application. The software is designed for on-premise deployment within a hospital's private network, utilizing a workstation with an advanced Graphics Processing Unit (GPU).
Compliance Status
INT Contour received FDA 510(k) clearance (K212274) on April 8, 2022, classifying it as a Class II medical device. It is intended as an initial method for segmentation and contouring, requiring subsequent review and editing by qualified medical professionals. The tool is also included in NICE's early value assessment for AI technologies in radiotherapy contouring, with ongoing evidence collection. CarinaAI provides services for AI development and 510(k) validation, including software like ContourQA that generates FDA-conforming reports.
Pricing Model
Pricing model details are not publicly disclosed. Interested parties are encouraged to contact CarinaAI directly for a demo and pricing information.
User Experience
The platform features an interactive study viewer for easy viewing and editing of segmentations. It offers advanced editing tools, including Smart Interpolation, to streamline the annotation process. Users can customize segmentation protocols and Treatment Planning System (TPS) options to fit their specific needs. The tool is generally well-received by Radiation Oncologists, with high satisfaction reported due to its intuitive features and time-saving capabilities.
Support Quality
CarinaAI offers integration support to ensure the AI tool fits seamlessly within existing clinical workflows. They also provide technical consulting for optimizing AI algorithms to meet specific requirements.
Implementation Complexity
INT Contour can be deployed as a standalone web-based system or integrated into existing workflows. It requires on-premise deployment within a hospital's private network on a workstation with an advanced GPU. CarinaAI provides integration support to facilitate smooth deployment. Initial setup may involve assigning specific contour models based on disease site.
Evidence Base
CarinaAI highlights scientific publications and white papers supporting its technologies. INT Contour has been included in retrospective studies and early value assessments by organizations like NICE, demonstrating its potential benefits in radiotherapy planning. Research indicates that AI autocontours are geometrically accurate and have a positive dosimetric impact, with good agreement to expert structures and significant time savings without compromising treatment plan quality after review. CarinaAI also mentions utilizing 'award-winning AI algorithms' and has strategic partnerships with leading hospitals for product testing and deployment.
Physician Tip

Always remember that INT Contour is intended as an initial segmentation tool; a thorough review and potential manual editing by a qualified medical professional are essential for clinical use. Leverage the customizable protocols and quality assurance reports to tailor the tool to your specific clinical guidelines and validate segmentation accuracy. Utilize the advanced editing features, like Smart Interpolation, to efficiently refine contours and maximize time savings in your workflow.

INT Contour offers flexible integration, functioning either as a standalone web-based system or connecting directly with your existing Treatment Planning Systems (TPS) via Automatic Workflow. Its ability to handle DICOM-RT data and deploy on-premise ensures compatibility with current hospital IT infrastructure and data security protocols.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentWeb-based system (stand-alone)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

INTContour received FDA 510(k) clearance (K212274) on April 8, 2022. It provides a machine learning-based approach for automatic segmentation of structures, including treatment targets and organs at risk, to support the radiation therapy treatment planning process. It is intended as an initial method for segmentation and contouring and must be used in conjunction with appropriate software to edit the segmentation results if necessary.
Integrations
EHR Not specified
Specialties Nuclear Medicine, Oncology, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate INT Contour

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PMC (PubMed Central)
Feasibility and impact of knowledge-based automated radiotherapy treatment planning in low- and middle-income countries
This peer-reviewed article discusses the feasibility and impact of knowledge-based automated radiotherapy treatment planning in low- and middle-income countries, referencing CARINA's INT Contour for AI-powered organ segmentation. The study, published in September 2025, highlights how AI-based auto-segmentation can reduce manual contouring time significantly, improving efficiency in resource-limited settings.
2025-09
ecancer
Feasibility and impact of knowledge-based automated radiotherapy treatment planning in low- and middle-income countries
This article, also published in September 2025, explores the use of knowledge-based auto-planning to enhance clinical efficiency and patient throughput in low- and middle-income countries, citing INT Contour as an AI-powered solution for organ segmentation. The research indicates that automated planning can lead to significant time savings and improved resource utilization.
2025-09
U.S. Food & Drug Administration (FDA)
U.S. Food & Drug Administration 510(k) Premarket Notification for INT Contour
This regulatory announcement from April 2022 details the FDA's review of Carina Medical LLC's 510(k) premarket notification for INT Contour, a software-only product for automatic segmentation of structures in medical images using machine learning. The document confirms the device's substantial equivalence to predicate devices and its safety and effectiveness for its intended use.
2022-04
Slideshare
Artificial Intelligence To Reduce Radiation-induced Cardiotoxicity In Lung Cancer Radiotherapy: A Novel Functional Radiomics Using Cardiac FDG-PET/CT
A presentation from an Assistant Professor/Computational Medical Physicist at Thomas Jefferson University, acknowledging a research software license for INT Contour from Carina Medical. The presentation discusses using AI to reduce radiation-induced cardiotoxicity in lung cancer radiotherapy through functional radiomics.
unknown

Videos

Product demos, reviews, and walkthroughs for INT Contour.

View all on YouTube

Frequently Asked Questions

INT Contour operates as a standalone web-based system and can also integrate with existing applications through Automatic Workflow or Treatment Planning System (TPS) Connectivity. It efficiently segments desired studies and transfers the results, typically in DICOM RTSTRUCT format, back to the main application for further use.
INT Contour has received FDA 510(k) clearance, indicating it is substantially equivalent to a legally marketed device for automatic segmentation in radiation therapy planning. While specific details on HIPAA/GDPR for INT Contour weren't explicitly detailed in the provided snippets, similar AI contouring solutions emphasize data protection through encryption and pseudonymization, which are standard practices for medical software dealing with Protected Health Information (PHI).
INT Contour is intended as an initial method for segmentation and contouring, meaning it must be used in conjunction with appropriate software for editing and requires thorough review by qualified medical professionals. While it offers incremental learning with on-site data, the accuracy and performance of these newly trained models are not assured by INT Contour.
No, INT Contour is designed to provide an initial, machine learning-based segmentation, but it does not eliminate the need for manual review. Physicians, dosimetrists, and medical physicists are expected to review and edit the AI-generated contours as necessary to ensure accuracy and patient safety in treatment planning.
Several other AI-powered auto-segmentation solutions are available for radiotherapy planning, including AI-Rad Companion Organs RT (Siemens Healthineers), ART-Plan (TheraPanacea), DLCExpert (Mirada Medical), Limbus Contour (Limbus AI), and Contour ProtegeAI (MIM Software). These systems also aim to improve contouring efficiency and consistency across various anatomical regions.
INT Contour supports automatic segmentation from CT, MRI, and PET/CT modalities. It can segment over 120 organs and lymph node groups across anatomical regions such as the head and neck, thorax, abdomen, and male pelvis.
While specific pricing for INT Contour was not found, AI auto-segmentation software is generally priced either through a fixed annual fee or on a per-patient basis. Physicians should consider that a per-patient model might incur higher costs if replans or daily CBCT image segmentations are frequent.

Related Tools

Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.
Cancer Copilot
Color Health
Oncology AI
Color Health's Cancer Copilot, built with OpenAI, helps oncologists and clinicians identify and order workup needs for recently diagnosed patients, aiming to speed up time to cancer treatment. This AI tool is designed to expand cancer expertise, speed decisions, and improve care, reducing a two-hour clinical task to 10 minutes with over 95% validated accuracy.
Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
Synapse Lung Nodule AI
Fujifilm Corporation
Oncology AI
Fujifilm's Synapse Lung Nodule AI is an AI software algorithm for detecting pulmonary nodules on CT imaging, aiming to support early detection and treatment of lung cancer.
On request
RadOncAI
Informai (for RadOncAI product) / Global Network for AI in Radiation Oncology (for RadoncAI.net)
Oncology AI
RadOncAI is an AI solution by Informai designed to optimize and enhance radiation oncology workflows, improving efficiency and accuracy in treatment planning and delivery.
FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.

See all Oncology AI tools →

Suggest an Edit → | Last Verified: 2026-04-20 | First Added: 2026-04-20

Investors who backed INT Contour

Funded through the company that built this tool.

Sunsino Venture Group
VC T3
Taipei, Taiwan
$250k-$1M
Sunsino Venture Group is a Taiwan-based investment firm with a long history in venture and growth investing across technology, manufacturing, life sciences,…
Biotech Medical Devices / MedTech
AI Tool Finder
AI-powered search. Results may not be comprehensive.